Compare CRSP & AUB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRSP | AUB |
|---|---|---|
| Founded | 2013 | 1902 |
| Country | Switzerland | United States |
| Employees | N/A | 3064 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.1B |
| IPO Year | 2016 | N/A |
| Metric | CRSP | AUB |
|---|---|---|
| Price | $49.80 | $40.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 8 |
| Target Price | ★ $70.29 | $41.88 |
| AVG Volume (30 Days) | ★ 1.7M | 875.1K |
| Earning Date | 05-11-2026 | 04-21-2026 |
| Dividend Yield | N/A | ★ 3.98% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $289,590,000.00 | N/A |
| Revenue This Year | $807.72 | $29.16 |
| Revenue Next Year | $172.52 | $4.59 |
| P/E Ratio | ★ N/A | $19.68 |
| Revenue Growth | ★ 9169.85 | N/A |
| 52 Week Low | $40.76 | $29.86 |
| 52 Week High | $78.48 | $42.18 |
| Indicator | CRSP | AUB |
|---|---|---|
| Relative Strength Index (RSI) | 45.11 | 66.51 |
| Support Level | $46.15 | $36.35 |
| Resistance Level | $59.61 | $40.71 |
| Average True Range (ATR) | 2.91 | 0.85 |
| MACD | -0.35 | 0.28 |
| Stochastic Oscillator | 9.92 | 97.45 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Atlantic Union Bankshares Corp is a financial and bank holding company based in the U.S. Through its community bank subsidiary and non-bank financial services affiliates, the company provides financial services, including banking, trust, and wealth management. It offers consumers and businesses a wide range of banking and related financial services, including checking, savings, certificates of deposit, and other depository services, as well as loans for commercial, industrial, residential mortgage, and consumer purposes. The company operates through two reportable operating segments: Wholesale Banking and Consumer Banking, with corporate support functions such as corporate treasury and others included in Corporate Other. It derives maximum revenue from the Wholesale Banking segment.